Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinical Trials
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Patient’s Voice
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinical Trials
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Patient’s Voice
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letter to the Editor
ARTICLE IN PRESS
doi:
10.25259/IJN_271_2025

Impact of Delayed Graft Function on Baseline Donor Derived Cell Free DNA in Kidney Transplant Recipients

Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, United States
Division of Nephrology and Hypertension, Medicine Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, United States

Corresponding author: Kalathil K Sureshkumar, Division of Nephrology and Hypertension, Medicine Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, United States

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Chopra B, Conant AN, Sureshkumar KK. Impact of Delayed Graft Function on Baseline Donor Derived Cell Free DNA in Kidney Transplant Recipients. Indian J Nephrol. doi: 10.25259/IJN_271_2025

Dear Editor,

Donor derived-cell free DNA (dd-cfDNA) is a serum biomarker useful for earlier prediction of acute rejection in kidney allografts.1-4 Baseline dd-cfDNA levels are <1% in 96% of kidney transplant recipients (KTRs).1 A dd-cfDNA level ≥ 1% suggests possible allograft injury, usually from acute rejection.2 We aimed to evaluate how delayed graft function (DGF) impacts baseline dd-cfDNA levels in kidney transplant recipients (KTRs).

We identified patients who underwent deceased donor kidney transplantation at our center between April 2018 and June 2020, who had dd-cfDNA measured 4-12 weeks post-transplant. A dd-cfDNA value ≥1.0% prompted allograft biopsy. Patients with biopsy evidence of rejection were excluded from the analysis. Patients were divided into 2 groups based on the presence or absence of DGF, which was defined as the need for dialysis during the first post-transplant week. The 4-12 week average and week 8 dd-cfDNA values were compared between the DGF and no-DGF groups using a t-test.

There were 80 deceased donor KTRs in the analysis (DGF, n=23; no-DGF=57) with 189 dd-cfDNA levels, including 56 in DGF and 123 in no-DGF groups. Average 4–12-week baseline dd-cfDNA levels were similar between DGF and no-DGF groups (0.39±0.21 vs. 0.49±0.44, p=0.17). Similarly, there was no significant difference in 8-week baseline dd-cfDNA levels between the two groups (0.30±0.18 vs.0.43± 0.45, p=0.07).

Despite the possibility of higher levels of ongoing intra-graft inflammation associated with DGF in KTRs,5 we did not observe higher baseline dd-cfDNA levels in these patients compared to KTRs who did not experience DGF. Our findings indicate that the development of DGF following kidney transplantation does not adversely impact the reliability of dd-cfDNA as a biomarker in predicting allograft rejection.

Acknowledgement

Presented orally during European Society of Organ Transplantation Congress 2021, Milan, Italy 2021.

Conflicts of interest

Dr. Kalathil Sureshkumar and Dr. Bhavna Chopra received research funding from CareDx.

References

  1. , , , , , , et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18:890-902.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28:2221-32.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  3. , , , et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int. 2022;101:793-803.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Cell-free DNA for the detection of kidney allograft rejection. Nat Med. 2024;30:2320-7.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  5. , , . Delayed graft function in the kidney transplant. Am J Transplant. 2011;11:2279-96.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]

Fulltext Views
165

PDF downloads
1,138
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections